Pharma and BRIC supplement
Almirall celebrates new offices in China to advance innovation in dermatology
The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners
AstraZeneca announces $2.5bn investment in China to boost R&D capabilities
The funds will go towards a new global research and development centre in Beijing’s BioPark
Infographic: Rare Diseases in China
How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.
Webcast: China Update 2023: How will recent developments impact your brand’s success?
Register for this live webinar in which emerging market experts provide an update regarding the implications of changing demographics and the healthcare landscape.
Sanofi and Innovent Biologics to develop oncology drugs for patients in China
Sanofi will make an initial equity investment of €300m in Innovent
Novo Nordisk growth takes a hit with China deal
Danish diabetes specialist Novo Nordisk cuts its growth forecast for 2022 following a value-based procurement deal with the Chinese government for its insulin products
Sinopharm’s COVID-19 vaccine scores approval in China
Vaccine found to be 79% effective in top-line results
Russia says its Sputnik V COVID-19 vaccine is 91.4% effective
Preliminary data demonstrates efficacy of 95% after 42 days
Russia submits COVID-19 vaccine to WHO for emergency use listing
Russia became first country to grant approval to a COVID-19 vaccine in August
Experimental Chinese COVID-19 vaccine is safe, according to researchers
Safety data was published on pre-print server medRxiv
Russia’s COVID-19 vaccine demonstrates early potential in Lancet report
However, there is too little data to definitively confirm efficacy